

Special Issue

Therapeutic Progress in Adult Acute Lymphoblastic Leukemia

Message from the Guest Editors

The turn of the century marked the new era of immunotherapy added to conventional chemotherapy and transplantation, leading to further improvement, while concurrent advances in molecular biology and genetics expanded our knowledge greatly about disease mechanisms and paved the way for risk/subset-oriented strategies and precision medicine. Thus, a long period of therapeutic stagnation in adult ALL therapy has ended, and recent trials document a global long-term survivorship of 50–60% for patients 18–60 years. The panel of ALL experts who kindly accepted our invitation for this Special Issue was assembled to highlight many (if not all) of these aspects, from diagnosis to risk classification and risk- or subset-oriented therapy. It is hoped that their excellent work will be appreciated by all those interested in adult ALL therapy and wishing to focus on the major therapeutic advancements achieved in the past 20 years, and those interested in the more promising new experimental approaches likely to affect the management of adult ALL subsets in the years to come.

Guest Editors

Prof. Dr. Renato Bassan

Hematology Unit, Ospedale dell'Angelo, Mestre-Venezia, Italy

Prof. Dr. Jose-Maria Ribera

Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Badalona, Spain

Deadline for manuscript submissions

closed (5 December 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/77506

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)